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LETTERS
Asymptomatic
Severe Acute
Respiratory
Syndrome–associ-
ated Coronavirus
Infection
To the Editor: An outbreak of
severe acute respiratory syndrome
(SARS) began in Hong Kong in
March 2003. As of May 29, 2003, a
total of 1,732 cases were confirmed;
381 case-patients were healthcare
workers and medical students.
Clinical features, treatment protocols,
and outcomes have been previously
reported by various local experts
(1–3). The etiologic agent is a SARS-
associated coronavirus (SARS-CoV)
(1). However, no asymptomatic case
of SARS-CoV infection has been pre-
viously reported (4). In addition, in
Hong Kong, blood donors have not
shown any detectable antibody to
SARS-CoV (1). We report a case of
possible asymptomatic SARS-CoV
infection in Hong Kong. 
The case-patient is a registered
nurse working in Princess Margaret
Hospital, the major infectious dis-
eases hospital that treated >600 SARS
patients in Hong Kong. Within this
hospital, >800 frontline staff members
have participated in direct care of
SARS patients, and SARS developed
in 62 of these staff members. All
healthcare workers working in SARS
wards followed the same infection
control measures, wearing a N-95 res-
pirator, eye shield, disposable cap,
water-resistant gown, and gloves.
Gowns and equipment were removed
before the staff left the SARS wards. 
We performed serologic testing of
the first 101 healthcare workers (doc-
tors, nurses, healthcare assistants)
who worked in the SARS wards but in
whom SARS did not develop. The
serologic testing was performed 7–8
weeks after the healthcare workers
were first exposed to SARS patients. 
We identified a nurse who was
asymptomatic for SARS-CoV infec-
tion, worked in the SARS ward since
the disease outbreak, and used full
infection control procedures as rec-
ommended by the World Health
Organization (WHO). The nurse per-
formed procedures, including
nasopharyngeal aspiration, handling
of fecal matter, and oral feeding of
SARS patients. SARS developed in
six colleagues who worked in the
same ward. She had unprotected
exposure to a colleague who contract-
ed SARS and required hospitalization.
Serologic testing for SARS-CoV anti-
body was performed in the microbiol-
ogy laboratory of Princess Margaret
Hospital on week 8 of the nurse’s
SARS ward duty. The result of the test
was positive by enzyme-linked
immunosorbent assay. The test was
repeated by the Government Virus
Unit of the Department of Health, one
of the reference laboratories in Hong
Kong. The second test also showed a
positive result with an antibody titer
of 400 by immunofluorescence assay
(normal: <25). We performed another
serologic test on week 10 of her
SARS ward duty; the result was again
positive. The nurse was interviewed
by two physicians and questioned
about her health condition since
February 2003. She did not report any
symptoms typical of SARS, such as
fever, chills, rigors, malaise, myalgia,
cough, dyspnea, and diarrhea (1,3)
during and after her SARS ward duty.
She did have a mild, short-term
headache, which she has had periodi-
cally for many years. She did not take
sick leave since February 2003. She
did not record any rise in body tem-
perature >37°C and had a leukocyte
count of 5.9 x 109/Land a lymphocyte
count of 1.6 x 109/L. Results of liver
and renal function tests were all nor-
mal. Reverse transcription-poly-
merase chain reaction results for
SARS-CoV in stool, urine, throat, and
nasal swabs collected during weeks
10 and 14 of her SARS ward duty
were all negative. No abnormal radio-
logic change was identified in the
lungs. She lived with four family
members and had close contact with
them. None of her family members
contracted SARS, and all showed a
negative result in the serologic testing
for SARS-CoV. 
We think that asymptomatic and
subclinical infection of SARS-CoV
exists and can result in seroconver-
sion; however, this kind of asympto-
matic seroconversion is probably
uncommon. Why a person infected
with SARS-CoV did not have typical
symptoms, and the infectivity of an
asymptomatic person is unknown. A
person’s genetic makeup may deter-
mine susceptibility to SARS-CoV and
the final clinical outcome. We agree
with Seto et al. (5) that recall bias is a
concern. However, recall bias proba-
bly had little effect since the events
took place recently. Moreover, the
hospitalization of the nurse’s infected
colleague would have made her more
alert and aware of symptoms of the
illness.
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Hepatitis C
Antibodies among
Blood Donors,
Senegal, 2001
To the Editor: Prevalence of
chronic hepatitis C virus (HCV)
among blood donors has been
assessed in a few West African coun-
tries; most recent estimates range
from 1.1% to 6.7% (1–4). A recent
meta-analysis of studies, including a
confirmation test, yielded an average
prevalence of HCV infection of 3.0%
(5). Until 2001, no systematic screen-
ing of HCV infection occurred among
blood donors in Senegal, and blood
donation legislation is still pending.
We report an assessment of the pro-
portion of blood donors from the
Hôpital Principal de Dakar who had
HCV antibodies in 2001. 
Blood donors were all volunteers,
recruited independently from the hos-
pitalized patients and registered in a
local donors association. We screened
for risk factors for bloodborne infec-
tions in potential donors through a
clinical examination and a confiden-
tial questionnaire. Persons with a his-
tory of jaundice or a risk behavior
were excluded. Serum samples col-
lected from blood donors from June to
December 2001 were screened for
HCV antibodies by a third-generation
enzyme immunoassay (EIA) (HCV
Murex 4.0; Abbott Laboratories,
Abbott, IL). Confirmation was per-
formed by a recombinant-immunoblot
assay (INNO-LIAHCVAb III update;
[Innogenetics, Gent, Belgium]). HCV
RNA was detected by a qualitative
reverse transcription–polymerase
chain reaction (Roche Amplicor HCV
test [Hoffman-LaRoche, Basel,
Switzerland]). Genotype was deter-
mined by the INNO-LiPA HCV II
assay (Innogenetics). Presence of hep-
atitis B surface antigen (HbsAg) and
alanine-aminotransferase (ALAT)
level are routinely assessed, as well as
HIV and human T-lymphotropic virus
type l infection.
The age of the 1,081 donors
ranged from 18 years to 61 years
(mean 35.6 years), and 81% were
men. First-time donors accounted for
31% and were younger than repeat
donors (mean 30.5 years vs. 37.8
years; p < 10–4). EIA HCV antibodies
were found in 18 donors (1.6%).
Immunoblot assay was positive for
nine, yielding an overall prevalence of
0.8% (exact 95% confidence interval
0.4% to 1.5%). Eight of the nine were
repeat donors, but the difference in
prevalence compared with first-time
donors did not reach statistical signif-
icance (1.1% vs. 0.3%). HCV-infected
donors tended to be older than unin-
fected donors (mean 42.3 years vs.
35.5 years, median 46.7 years vs. 34.6
years, Mann-Whitney test p = 0.04),
and the trend with age was significant
(18–29 years 0.3%; 30–39 years
0.6%; 40–49 years 1.5%; >50 years
1.8%; chi-square trend = 4.39; p =
0.03). ALAT levels of infected study
participants were in the normal range
(17–55 IU). One participant had an
ALAT level above normal. Genotype
2ac has been identified on line
immunoassay–positive samples (three
samples not tested). HBsAg was
detected in 13% of the new donors.
No co-infection with HCV and hepa-
titis B virus was found.
The prevalence of HCV antibodies
in blood donors in Dakar in 2001
appears to be one of the lowest in
West Africa, close to published esti-
mates for Mauritania and Benin (1.1%
and 1.4%, respectively) and lower
than in other West African countries
such as Ghana or Guinea, where
prevalence ranges from 2.8% to 6.7%
(1–4). This finding is in keeping with
results of a hospital case-control study
on HCV infection and liver cirrhosis
or cancer, conducted in 1995 in
Dakar. While that study did not iden-
tify HCV infection in 73 controls, 2 of
73 case-patients (2.7%) had HCV
antibodies (6). Conversely, high HCV
prevalence was found in groups at
risk: antibodies were present in 12 of
15 hemodialysis patients, and HCV
RNA was found in 6 of the 12 HVC
antibody-positive patients (genotype
2ac, the same as in our study); 7% of
a cohort of 58 HIV-1 patients receiv-
ing highly active antiretroviral thera-
py had a positive HCV serologic
result (7,8). 
In the urban setting of Dakar, HCV
infection seems still to be confined to
groups at risk. The contribution of
HCV to chronic liver diseases has not
been yet demonstrated. Approx-
imately 15,000 blood donations are
annually made in Dakar. A systematic
screening of HCV antibodies in blood
donors could prevent, on average, 120
bloodborne HCV infections each year.
Given these data and the price of EIA
and LIA, the screening cost per HCV-
positive sample identified, and infec-
tion subsequently averted, is approxi-
mately 200,300 CFA(U.S.$305). This
estimate is low since it includes only
the marginal cost of the reagent kits.
This screening cost could be reduced
by discarding blood units that test
positive after only one enzyme-linked
immunosorbent assay (156,000 CFA
or U.S.$237), at the price of nearly
3% of blood units wrongly discarded.
France has demonstrated that this
strategy has the best cost-effective-
ness ratio, as long as the prevalence
remains below 8% (9). This cost com-
pares favorably with the cost per HIV
infection averted through improve-
ment of blood safety (range
U.S.$20–U.S.$1,000), assessed in
some highly HIV-prevalent southern
African countries (Tanzania, Zambia,
Zimbabwe) (10). The HCV-positive
discarded blood units will be added to
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